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Abstract
Observational studies have reported an inverse association between serum 25-hydroxyvitamin D (25OHD) concentrations and
Staphylococcus aureus nasal carriage; however, clinical trials of vitamin D supplementation are lacking. To assess the effect of vitamin D3
supplementation on persistent S. aureus nasal carriage we conducted a randomized, double-blind, placebo-controlled trial among 322
healthy adults. Participants were given an oral dose of either 200 000 IU vitamin D3 for each of 2 months, followed by 100 000 IU monthly
or placebo in an identical dosing regimen, for a total of 18 months. Nasal swabs for S. aureus culture and serum for 25OHD measurement
were obtained at baseline, 6, 12 and 18 months of study. The mean baseline concentration of 25OHD was 72 nM (SD 22 nM). Vitamin D3
supplementation increased 25OHD levels which were maintained at >120 nM throughout the study. Nasal colonization by S. aureus was
found in 31% of participants at baseline. Persistent carriage, deﬁned as those that had positive S. aureus nasal cultures for all post-baseline
swabs, occurred in 20% of the participants but vitamin D3 supplementation was not associated with a reduction in persistent carriage
(OR = 1.39, 95% CI 0.63–3.06). Risk factor analysis showed that only gender was signiﬁcantly associated with carriage, where women were
less likely to be carriers than men (relative risk 0.83, 95% CI 0.54–0.99). Serum 25OHD concentrations were not associated with the risk of
carriage. In conclusion, monthly administration of 100 000 IU of vitamin D3 did not reduce persistent S. aureus nasal carriage.
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Introduction
Nasal carriage of Staphylococcus aureus is an important risk
factor for staphylococcal infection [1–3]. The determinants
of carriage itself are a complex interplay between host and
bacterial elements which are only partly understood [4–7].
Carriage prevalence is consistently higher in infants and
children, hospitalized patients or those recently hospitalized
[8–10], and is often higher in men than women [11,12].
The elderly (≥65 years) are more likely to carry methicillin-
resistant S. aureus, although the overall prevalence of
S. aureus carriage is similar to that in younger adults
[13,14]. Less deﬁnitive is the effect of ethnicity on carriage;
some studies report higher carriage rates among white
individuals [11,15,16], whereas others show either no
ethnic differences [9,12] or a lower prevalence in white
individuals [14,17].
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Few modiﬁable risk factors for carriage have been conﬁrmed
in community-based studies, with unconﬁrmed or conﬂicting
results for smoking [12,18,19], healthcare work [10,20] and
hormonal contraceptive use [21]. Recently, two observational
studies suggested that low vitamin D status may be associated
with higher rates of S. aureus nasal carriage [18,22]. It is
biologically plausible that vitamin D status could affect S. aureus
nasal carriage, because vitamin D plays an important role in
innate immunity by inducing the expression of antimicrobial
peptides, such as cathelicidin, which has both antimicrobial and
antibioﬁlm activity against S. aureus in vitro [23].
The Vitamin D and Acute Respiratory Infections Study
(VIDARIS) was a double-blind randomized placebo-controlled
trial of vitamin D3 supplementation, designed to assess the
effect of supplementation on acute respiratory infections
among healthy adults [24]. A pre-speciﬁed secondary aim was
to assess the effect of vitamin D supplementation on preva-
lence of persistent S. aureus nasal carriage over 18 months. In
addition, the collection of comprehensive baseline clinical data
and regular measurement of both S. aureus nasal carriage and
serum 25OHD concentrations enabled analysis of risk factors
for staphylococcal carriage in this group of healthy adults at
each time-point.
Methods
Design, participants and randomization
VIDARIS was a randomized, double blind, placebo-controlled
trial based in Christchurch, New Zealand, and is described in
detail elsewhere [24]. Brieﬂy, participants were staff or
students of the Canterbury District Health Board or the
University of Otago, Christchurch who were aged ≥18 years.
Volunteers were excluded from the study if they had any of
the following features: use of vitamin D supplements where
daily intake exceeded 400 IU, use of immunosuppressants or
medications that interfere with vitamin D metabolism, known
history of hypercalcaemia, nephrolithiasis, sarcoidosis, kidney
disorders requiring dialysis, polycystic kidney disease, cirrhosis,
a current malignancy diagnosis with poor prognosis, or
baseline plasma calcium >2.6 or <2.1 mM, and women who
were pregnant or planning to become pregnant. The study was
approved by the Upper South B Regional Ethics Committee
and is registered with the Australian and New Zealand Clinical
Trials Registry; ACTRN12609000486224. All participants
provided written informed consent.
Baseline characteristics were obtained by interviewer-
administered questionnaire and included age, gender, ethnicity,
smoking status, occupation, height, weight and calculated body
mass index, New Zealand Deprivation (NZDep) score,
medical history, current medications and supplement usage.
Participants that self-identiﬁed as either ‘Maori/Paciﬁc’ ethnic-
ity or those that were current smokers were categorized
separately for analysis. Patient contact at work was divided
into either ‘some’ or ‘none’ determined by the participant’s
occupation. Socioeconomic status was measured using the
NZDep score based on the participant’s residential address
(Table 1). NZDep uses nine variables collected in the 5-yearly
New Zealand Census to rank the socioeconomic status of
small geographic areas (90 households per area) [25].
Geographic areas were divided into quintiles with quintile ﬁve
being the poorest areas, and quintile one being the wealthiest
areas.
Participants randomized to the active treatment received
oral vitamin D3 200 000 IU at study initiation, another
200 000 IU 1 month later, and then 100 000 IU monthly
thereafter for a total of 18 months. Those randomized to
placebo received matching inactive tablets administered in an
identical dosing regimen to the active treatment. Both vitamin
D3 and placebo tablets were sourced from Tishcon Corp
(Westbury, NY, USA) and were identical in appearance. The
participants and study personnel conducting the trial were
blind to treatment allocation.
TABLE 1. Participant characteristics by randomly assigned
group
Characteristic
Vitamin D
(n = 161)
Placebo
(n = 161)
Age (years) 47  10 48  10
Female 121 (75) 120 (75)
Maori/Paciﬁc ethnicitya 7 (4) 8 (5)
Current smoker 6 (4) 11 (7)
Patient contact at work
Some contact 104 (65) 93 (58)
No contact 57 (35) 68 (42)
Height (cm) 168  9 168  9
Weight (kg) 77  15 78.0  15
BMI (kg/m2)b 27  5 28  5
NZDep quintilec
5 (poorest) 1.00 (reference group)
4 1.18 (0.56–2.48)
3 0.94 (0.44–1.98)
2 0.89 (0.42–1.89)
1 (wealthiest) 0.77 (0.37–1.58)
Diabetes 3 (2) 1 (1)
Staphylococcus aureus nasal colonization 40 (25) 60 (37)
Baseline serum 25-OHD (nM)
<50 20 (12) 25 (16)
50–74 68 (42) 70 (43)
≥75 73 (45) 66 (41)
Mean post-baseline serum 25-OHD (nM)d
<50 0 45 (28)
50–74 2 (1) 79 (49)
≥75 158 (99) 37 (23)
Values are means ( standard deviation) and numbers (% within treatment arm).
aSelf-identiﬁed as Maori/Paciﬁc ethnicity, which includes: Samoan, Cook Islands
Maori, Tongan, Niuean, Fijian, Tokelauan, Tuvaluan.
bBMI, body mass index; calculated as the ratio of weight (kg): height (m2).
cNZDep: New Zealand Deprivation Score, based on residential address.
dOne person in the treatment arm had no post-baseline 25-hydroxy vitamin D (25-
OHD) measurements.
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Follow up and outcomes
After randomization, follow-up visits occurred monthly to the
end of the study. During these visits, dedicated study staff met
the participants in person to administer the monthly dose of
vitamin D or placebo and to conduct a brief interview.
Non-fasting blood samples were taken at baseline, 6, 12 and
18 months of study and were stored at 80°C until each
participant completed the study. The 25OHD concentrations
were measured by liquid chromatography-tandem mass
spectrometry (ABSciex API 4000, Framingham, MA, USA)
and the results were unknown to the study team until after
data collection was completed at the end of the study period.
At baseline, 6, 12 and 18 months of study, samples for
S. aureus culture were obtained by rotating a sterile cotton-
tipped swab into both anterior nares and placing the swab in
Amies transport medium (Copan, Brescia, Italy). Swabs were
incubated overnight at 35°C in a selective enrichment broth
containing colistin, aztreonam, mannitol and 2.5% sodium
chloride. The broth was then inoculated onto chromogenic
staphylococcus agar (Fort Richard Laboratories, Auckland,
New Zealand) and incubated at 35°C for 18–24 h.
Presumptive (pink) S. aureus colonies were then identiﬁed by
standard microbiological methods, including the coagulase test.
Virtually all nasal swab specimens were cultured within 6 h of
collection. There was a longer delay between collection and
culture in a small number of cases (fewer than ten specimens)
because the participants were not in Christchurch at the time
of collection.
The primary outcome was persistent S. aureus nasal
carriage. A positive swab was deﬁned as the presence of one
or more colonies of S. aureus on the culture plate. Persistent
staphylococcal carriers were deﬁned as those with positive
nasal cultures for S. aureus on all three post-baseline swabs,
whereas non-carriers were negative on all three post-baseline
swabs. Those participants who were positive on some but not
all post-baseline swabs (i.e. ‘intermittent carriers’) were
included with the ‘non-carriers’.
Statistical analyses
Logistic regression was used to assess the effect of vitamin D
supplementation on persistent carriage over the 18-month
study period, taking into account baseline carriage. This
analysis included only participants who had a swab taken at
all four data collection points (n = 304).
To assess the baseline characteristics as potential determi-
nants of S. aureus carriage, each data collection point was
considered separately and the outcome was isolation of
S. aureus on the nasal swab. A generalized linear mixed model
was used to take into account repeated measures. This models
the covariance structure between the repeated measures for
each person and uses a regression model with Poisson
distribution, log link and ‘sandwich’ variance estimates to
model the ﬁxed effects. An autoregressive covariance
structure was used. The model was ﬁtted both with 25OHD
level as a continuous variable and with 25OHD level
dichotomized into ‘low’ (<50 nM) and ‘not low’ (≥50 nM).
All statistical tests were two-tailed and considered signif-
icant when p values were <0.05. The statistical software used
was SAS, version 9.2 (SAS Institute Inc.).
Results
A total of 322 eligible participants were randomly assigned to
one or other treatment arm. Two hundred and ninety-four
(91%) completed the study on treatment, 18 (6%) withdrew
from the study and ten (3%) withdrew from treatment but
completed the 18-month study (Fig. 1). A total of 304
participants had swabs taken at baseline and all three follow-up
times.
Table 1 shows the baseline characteristics of the 322
participants. Overall, the mean age at recruitment was
47 years and 241 (75%) were female. The placebo group had
a higher prevalence of S. aureus nasal colonization at baseline;
otherwise the groups were evenly balanced for all character-
istics. Supplementation was highly effective in increasing serum
25OHD levels where mean post-baseline concentrations
ranged from 57 to 227 nM, whereas in the placebo group
mean concentrations ranged from 18 to 142 nM [24].
Table 2 shows that in the treatment and placebo groups,
most participants who were non-carriers at baseline remained
so and about 60% of those who were colonized at baseline
continued to be colonized at all subsequent time points. Only
one nasal culture was methicillin-resistant S. aureus positive.
Overall, 62 of the 304 participants (20%) that provided all
three post-baseline samples had persistent carriage as per our
deﬁnition. Logistic regression taking baseline carriage into
account found that vitamin D supplementation did not reduce
the prevalence of persistent carriage compared with placebo
(OR = 1.39, 95% CI 0.63–3.06).
The results of the generalized mixed model that assessed
risk factors for S. aureus carriage are shown in Table 3. The
serum level of 25OHD at the time the swab was taken was not
related to the risk of carriage, whether it was considered as a
continuous variable (Table 3) or when categorized into ‘low’
(<50 nM) and ‘not low’ (≥50 nM) groups (relative risk for low
25OHD = 1.03; 95% CI 0.86–1.23). Women were less likely
to be carriers than men (relative risk = 0.83, 95% CI 0.54–
0.99). Other potential risk factors showed no signiﬁcant
correlation with S. aureus carriage.
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Discussion
To our knowledge, this is the ﬁrst randomized controlled trial
to report the effect of vitamin D supplementation on S. aureus
nasal carriage. We found that monthly doses of 100 000 IU
vitamin D3 for 18 months did not signiﬁcantly reduce the
prevalence of persistent S. aureus nasal carriage in healthy
adults. In addition, serum 25OHD levels were not associated
with S. aureus carriage at any point during an 18-month period.
We were unable to identify any participant characteristics
other than gender as a risk factor for carriage in this sample of
healthy adults.
The strengths of our study include the randomized
supplementation and the repeated measures of 25OHD levels
351 VIDARIS participants 
assessed for eligibility  
29 withdrew during screening or did not 
meet entry criteria
161 allocated to receive vitamin D  
8 discontinued treatment but had all 
4 nasal swabs cultured 
161 allocated to receive placebo 
146 completed the 
study on treatment and 
had all 4 nasal swabs 
cultured
7 withdrew from study and had < 4 
nasal swabs cultured 
2 discontinued treatment but had all 4 
nasal swabs cultured 
148 completed the 
study on treatment and 
had all 4 nasal swabs 
cultured
11 withdrew from study and had < 4 
nasal swabs cultured
Randomly assigned (n = 322)
304 participants were included in the effect of supplementation analysis
FIG. 1. Study ﬂow diagram.
TABLE 2. Effect of supplementation; 304 participants with
four nasal swabs
Number of
positiveswabs
after baseline
Carrier at baseline Non-carrier at baseline
Vitamin D
(n = 40),
n (%)
Placebo
(n = 57),
n (%)
Vitamin
D (n = 110),
n (%)
Placebo
(n = 97),
n (%)
0 4 (10) 9 (16) 82 (75) 80 (83)
1 6 (15) 8 (14) 18 (16) 13 (13)
2 5 (13) 6 (11) 7 (6) 4 (4)
3 25 (63) 34 (60) 3 (3) 0
TABLE 3. Risk factors for Staphylococcus aureus nasal car-
riage
Relative
risk 95% CI
p
value
Model 1
Age (per 5 years) 0.97 0.90–1.04 0.35
Female 0.83 0.54–0.99 0.04
Maori/Paciﬁc ethnicity 1.16 0.66–2.03 0.61
Current smoker 0.88 0.45–1.70 0.70
Patient contact at work 0.98 0.73–1.31 0.90
BMI (per kg/m2)a 1.00 0.98–1.03 0.76
NZDep quintileb
5 (poorest) 1.00 Reference group
4 1.18 0.56–2.48 0.67
3 0.94 0.44–1.98 0.86
2 0.89 0.42–1.89 0.75
1 (wealthiest) 0.77 0.37–1.58 0.47
25OHDc (per 5 nM increase) 1.01 1.00–1.02 0.11
aBMI, body mass index; calculated as the ratio of weight (kg), height (m2).
bNZDep, New Zealand Deprivation Score, based on residential address.
c25OHD, 25-hydroxy vitamin D.
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and nasal cultures over 18 months. The prevalence of
persistent S. aureus nasal carriage in our study population
(20%) was similar to rates previously reported within the
general community [3,17]. Limitations include the relatively
small sample size and low numbers of men, current smokers
and Maori/Paciﬁc participants, which limit our ability to assess
these characteristics as risk factors for S. aureus carriage. We
may have misclassiﬁed carriage status in some cases through
failure to obtain an adequate sample or the laboratory not
detecting the presence of S. aureus. We did not perform
quantitative measures of S. aureus colonization, so cannot
determine whether vitamin D might have reduced the amount
of S. aureus in the nose without eliminating it. A further
possible limitation of our study could be the dosing regimen
employed. It is plausible that some conditions may be more
responsive to a lower more frequent dose of vitamin D and
several mechanisms have been proposed by which the immune
system could be affected by different vitamin D dosing
regimens [26].
van Belkum and colleagues have suggested that the
important distinction is between ‘persistent’ carriage and
other states (including non-carriage and intermittent carriage),
because of a higher risk of clinical infection with persistent
carriage [27]. We therefore chose to assess the effect of
supplementation on persistent carriage during the study only.
We did not have measures of carriage in the period before the
study, so could not assess the effect of vitamin D supplemen-
tation according to prestudy carriage type. Various deﬁnitions
of ‘persistent carriage’ have been proposed [3,27]. A recent
study concluded that three positive consecutive samples or
one or two quantitative samples were adequate to identify
persistent carriers when compared with a reference standard
[28]. Nonetheless, identiﬁcation of carriage status as
persistent, intermittent or non-carriage depends on the
number and timing of specimens taken. In our study the
specimens were taken at 6-month intervals, so it is possible
that with more frequent sampling some of our persistent
carriers would be deﬁned as intermittent carriers. In addition
we could not distinguish those who carried a single strain for
the whole study period from those whose carried strains
changed over time. On the other hand, our deﬁnition of
persistent carriage, requiring carriage at each sampling point
over an 18-month period, could be considered to set a high
threshold for persistence.
Two observational studies have reported associations
between serum 25OHD concentrations and carriage. In a
cross-sectional study of 14 000 American adults and children,
vitamin D deﬁciency (<50 nM), was associated with a higher
risk of methicillin-resistant S. aureus nasal carriage, but not
methicillin-susceptible S. aureus carriage, based on a single
swab [22]. In a Norwegian population, investigators found a
statistically signiﬁcant association between serum 25OHD
concentrations and S. aureus nasal carriage on two swabs in
white, non-smoking males [18]. In this subgroup, participants
with 25OHD concentrations ≥75 nM were about half as likely
to have one or two positive swabs compared with those with
concentrations <50 nM; moreover, every 5 nM increase in
serum 25OHD concentration was associated with an approx-
imately 7% decrease in the probability of S. aureus nasal
carriage [18]. However, this association was not found in
women or in smokers. It is unclear if this stratiﬁcation by sex
and smoking status was an analysis designed to test a
prespeciﬁed hypothesis or if it was performed as an
exploratory analysis.
Comparing the results of different studies is complicated
because different measures of carriage are used. Although our
study design was different from those above, our analysis of
risk factors for carriage was able to assess the effect of
25OHD level on S. aureus carriage at a particular time point,
so our results are broadly comparable. We did ﬁnd that
carriage was more common in men, but neither smoking status
nor 25OHD level was signiﬁcantly associated with carriage,
and ‘vitamin D deﬁciency (<50 nM)’ was also not associated
with carriage. Although our cohort had a level of S. aureus
nasal colonization similar to the Norwegian population, we had
a lower proportion of participants with vitamin D deﬁciency,
with only 14% having baseline levels <50 nM, compared with
46% of the non-smoking Norwegian participants. This
combined with the low numbers of men and smokers in our
study population may be contributing factors to the seemingly
contradictory ﬁndings between the two studies.
In conclusion, we found no effect of monthly administration
of 100 000 IU doses of vitamin D on carriage among a healthy
adult population with little deﬁciency. Further studies are
required to assess whether vitamin D supplementation is
beneﬁcial in other populations, and could also assess whether
supplementation reduces the S. aureus load, its effects in
identiﬁed persistent carriers, and on strain persistence. Long-
term follow-up studies are needed to conﬁrm the importance
of different patterns of carriage and other risk factors for
clinically important infections. However, if vitamin D supple-
mentation and 25OHD levels are unrelated to carriage in
healthy adults, it seems unlikely that they will be related to
illness risk in this large segment of the general population.
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